1
Return

Targeting vulnerabilities in IDH mutant tumours: The model matters

delete2026-07-27
delete0
delete
OA
AI
A
Alwine B. Kruisselbrink
T
Tessa Wilpshaar
I
Ieva Palubeckaitė
R
Romy C. Dijkland
T
Tatiana Belova
S
Sara Cardoso
P
Pauline M. Wijers‐Koster
I
Inge H. Briaire‐de Bruijn
R
René J. M. van Zeijl
H
Hans Dalebout
M
Marieke L. Kuijjer
H
Hailiang Mei
B
Bram Heijs
K
Károly Szuhai
J
Judith V.M.G. Bovée *
S
Sanne Venneker
DOI:10.1016/j.neo.2026.101338delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
• The model system influences therapeutic vulnerabilities in IDHMUT cell lines. • Therapeutic vulnerabilities in non-endogenous IDHMUT models may be model artifacts. • IDHMUT overexpression and high D-2-HG levels induce treatment sensitivities. • Non-endogenous IDHMUT models can generate false positive therapeutic leads. • Use of endogenous IDHMUT models is recommended for clinical translation.
Keywords:
IDH1/IDH2 mutations
D-2-hydroxyglutarate
synthetic lethality
in vitro models
CRISPR-Cas9
chondrosarcoma
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Neoplasia cover
Neoplasia
IF:
7.7
Papers:
2.8K
Citations:
8.0K

Organization

L
leiden university medical center
Scholars:
1.1K
Papers: 378
Citations: 0
U
University of Oslo
Scholars:
2.9K
Papers: 1.3K
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers